It also reduces gastrointestinal motility, aiding in the stabilization of blood glucose levels in type 2 diabetes after therapy with exogenous GLP-1, and enhances satiety, with a consequent reduction in food intake [52]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.